Published in Urol Oncol on January 31, 2012
Confocal laser endomicroscopy of bladder and upper tract urothelial carcinoma: a new era of optical diagnosis? Curr Urol Rep (2014) 0.87
A Pilot Study of In Vivo Confocal Laser Endomicroscopy of Upper Tract Urothelial Carcinoma. J Endourol (2015) 0.81
Urinary cytology with acridine orange fluorescence is highly valuable for predicting high-grade upper urinary tract urothelial carcinoma. Int J Clin Exp Pathol (2014) 0.77
Urothelial carcinoma: Endoscopy to predict outcomes in upper tract urothelial cancer. Nat Rev Urol (2012) 0.77
Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. Oncotarget (2017) 0.75
The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatory. Can Urol Assoc J (2017) 0.75
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13
Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11
Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74
Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70
Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54
High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51
Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol (2011) 1.51
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology (2010) 1.49
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46
Postprostatectomy incontinence: all about diagnosis and management. Eur Urol (2008) 1.44
Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43
The complex structure of the smooth muscle layer of spermatic veins and its potential role in the development of varicocele testis. Eur Urol (2006) 1.43
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol (2013) 1.43
Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urology (2010) 1.42
Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol (2009) 1.40
Perioperative betamethasone treatment reduces signs of bladder dysfunction in a rat model for neurapraxia in female urogenital surgery. Eur Urol (2012) 1.37
Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med (2010) 1.35
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol (2009) 1.22
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int (2009) 1.21
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res (2007) 1.20
Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology (2010) 1.18
Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol (2009) 1.15
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol (2010) 1.14
Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol (2009) 1.14
Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology (2007) 1.12
Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences. Urology (2008) 1.12
Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol (2007) 1.12
Monitoring the coupling of the lithotripter therapy head with skin during routine shock wave lithotripsy with a surveillance camera. J Urol (2011) 1.11
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer (2009) 1.08
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06
Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol (2012) 1.05
Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol (2006) 1.05
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res (2006) 1.04
Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol (2010) 1.02
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01
Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol (2009) 1.01
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int (2010) 0.99
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol (2010) 0.99
High-power diode laser at 980 nm for the treatment of benign prostatic hyperplasia: ex vivo investigations on porcine kidneys and human cadaver prostates. Lasers Med Sci (2008) 0.98
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology (2008) 0.98
Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol (2007) 0.97
Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model. J Urol (2005) 0.96
CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol (2009) 0.95
Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int (2005) 0.93
Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int (2009) 0.92
Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol (2009) 0.92
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int (2010) 0.91
In vitro investigations of repulsion during laser lithotripsy using a pendulum set-up. Lasers Med Sci (2011) 0.90
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol (2010) 0.90
Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol (2003) 0.90
Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol (2009) 0.90
Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol (2010) 0.89